Exhibit (d)(3)
CONFIDENTIALITY AGREEMENT
1 | Effective Date. This Agreement is entered into and effective as of the latest date of signature appearing below (the “Effective Date”). |
2 | Parties. The parties to this Agreement and their addresses are: |
| | |
UCB Biopharma SPRL | | Zogenix, Inc. |
Allee de la Recherche 60 | | 5959 Horton Street |
Brussels, 1070 | | Emeryville, CA 94608 |
Belgium | | United States |
| |
(“UCB”) | | (“Zogenix”) |
3 | Purpose. The purpose of the disclosure of Confidential Information is to evaluate, discuss and/or negotiate a potential business transaction between the parties (or their respective Affiliates) for a commercial relationship in Europe related to Zogenix’s proprietary product known as Fintepla® (fenfluramine) (the “Purpose”). |
4 | Disclosing Party and Receiving Party. Confidential Information may be disclosed under this Agreement by or on behalf of each of the parties in connection with the Purpose. In each case, the party disclosing Confidential Information is referred to herein as the “Disclosing Party” and the party receiving Confidential Information is referred to herein as the “Receiving Party”. |
5 | Confidential Information. |
As used in this Agreement the term “Confidential Information” means any confidential and/or proprietary data or information which is disclosed or otherwise made available by or on behalf of the Disclosing Party to the Receiving Party, whether in oral, visual, written, electronic, or any other form. Information to which the Receiving Party gains access during visits to the facilities of the Disclosing Party or its Affiliates shall also be Confidential Information.
Confidential Information may include, but is not limited to (i) data, know-how, formulas, processes, documents, designs, plans, graphs, drawings or specifications, (ii) software, source or object codes, algorithms, or information about the methods, concepts and techniques on which software is based, (iii) chemical structures, amino/nucleic acid sequences, structural biology, or descriptions of any devices, cell lines or molecular models, (iv) clinical trial protocols, assays, services, studies, results, findings, inventions, ideas and other knowledge, (v) information regarding patent applications and patents, trademarks or
Page | 1